Product Description
Mechanisms of Action: KAR Antagonist,AMPA Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Tinnitus|Epilepsy, Reflex|Seizures|Muscle Spasticity|Migraine Disorders|Multiple Sclerosis|Epilepsy|Migraine with Aura|Migraine without Aura|Adrenocortical Adenoma|Sarcoma, Endometrial Stromal|Adenoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-7041-83/hah | N/A |
Not yet recruiting |
Depressive Disorder |
2021-05-28 |
|
CBGG492A2215 | P2 |
Withdrawn |
Multiple Sclerosis|Muscle Spasticity |
2018-03-01 |
|
CBGG492A2214 | P2 |
Withdrawn |
Migraine Disorders |
2016-11-01 |
|
2013-003431-29 | P2 |
Completed |
Adenoma |
2015-09-21 |